c met inhibitor (Selleck Chemicals)
Selleck Chemicals is a verified supplier 
Selleck Chemicals manufactures this product 
96
Structured Review
Selleck Chemicals
c met inhibitor
C Met Inhibitor, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 368 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c+met+inhibitor/Crizotinib/pmc12847976-21-7-10
Average 96 stars, based on 368 article reviews
C Met Inhibitor, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 368 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c+met+inhibitor/Crizotinib/pmc12847976-21-7-10
Average 96 stars, based on 368 article reviews
c met inhibitor - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Control:Article Title: HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis Article Snippet: .. The mice were then treated for a further 5 weeks with either vehicle control, HGF inhibitor (ZFH-7116, Department of Biochemistry and Molecular Biophysics at Washington University in St. Louis, USA), Article Title: HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis. Article Snippet: .. The mice were then treated for a further 5 weeks with either vehicle control, HGF inhibitor (ZFH-7116, Department of Biochemistry and Molecular Biophysics at Washington University in St. Louis, USA), Article Title: Superiority of Intestinal Adaptation by Hepatocyte Growth Factor in the Jejunum: An Experimental Study in a Short-bowel Rat Model. Article Snippet: Background: We evaluated the effect of recombinant human hepatocyte growth factor (rh-HGF) on intestinal adaptation in a rat model of short-bowel syndrome (SBS).. Methods: SpragueeDawley rats underwent jugular vein catheterization for continuous total parenteral nutrition (TPN) and 90 % small bowel resection.. The animals were divided into 3 groups: TPN/SBS (control group, n 1⁄4 7), TPN/SBS/intravenous recombinant human hepatocyte growth factor (HGF) (0.3 mg/kg/day) (HGF group, n 1⁄4 7), and TPN/SBS/intravenous c-Met inhibitor (0.3 mg/kg/day) (anti-HGF group, n 1⁄4 5). |